SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Mel Spivak who wrote (61)12/2/1997 10:06:00 PM
From: CPAMarty  Read Replies (1) | Respond to of 2515
 
Not sure what is behind the bounce. We had some very nice news on IMCL right after the market came down with the Hong Cong Flu. Perhaps some investors waited to get in after the recent rise in the general market.



To: Mel Spivak who wrote (61)12/3/1997 1:41:00 PM
From: CPAMarty  Respond to of 2515
 
NEW YORK, Dec 3 (Reuters) - Salomon Smith Barney analyst Franklin Berger said he initiated coverage of ImClone Systems Inc with a V1 rating, a buy rating with a venture capital risk rating.

set 12-month price target of $12 on the stock, which rose 3/16 to 7-3/8.

said in report: "We forecast strong 1998 news flow from multiple clinical trials and potential new partnerships to focus investor attention on ImClone."

REUTERS

12:37 12-03-97


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News